Document is current
Any future updates will be listed below
-
Authors
Kimishima, Yusuke https://orcid.org/0000-0003-4470-2365
Misaka, Tomofumi https://orcid.org/0000-0003-4795-9334
Yokokawa, Tetsuro https://orcid.org/0000-0001-8197-3274
Wada, Kento
Ueda, Koki https://orcid.org/0000-0002-6964-7035
Sugimoto, Koichi
Minakawa, Keiji
Nakazato, Kazuhiko
Ishida, Takafumi
Oshima, Motohiko
Koide, Shuhei
Shide, Kotaro
Shimoda, Kazuya https://orcid.org/0000-0002-2555-8188
Iwama, Atsushi https://orcid.org/0000-0001-9410-8992
Ikeda, Kazuhiko https://orcid.org/0000-0002-5269-269X
Takeishi, Yasuchika
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (JP19K17609)
MEXT | Japan Society for the Promotion of Science (JP19K08523)
Uehara Memorial Foundation (201890006)
- License Information
-
More Information
Article History
Received: 11 May 2020
Accepted: 5 October 2021
First Online: 26 October 2021
Competing interests
: T.M. department is supported by Fukuda Denshi Co., Ltd., Japan. T.Y. and K.S. department is supported by Actelion Pharmaceuticals Japan, Ltd., Japan. Ruxolitinib was provided by Novartis Pharmaceuticals to K.I.. These companies were not associated with the contents of this study. All other authors declare no competing interests.
